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Use of the inactivated intranasal influenza vaccine and the risk of
Bell's palsy in Switzerland
Abstract
BACKGROUND: After the introduction of an inactivated intranasal influenza vaccine that was used
only in Switzerland, 46 cases of Bell's palsy were reported. METHODS: We conducted a matched
case-control study and a case-series analysis. All primary care physicians, ear, nose, and throat
specialists, and neurologists in German-speaking regions of Switzerland were requested to identify cases
of Bell's palsy diagnosed in adults between October 1, 2000, and April 30, 2001. Each physician was
invited to select three control patients for each patient with Bell's palsy, with matching according to age,
date of the clinic visit, and physician. Vaccination information was provided by the physicians.
RESULTS: A total of 773 patients with Bell's palsy were identified. Of the 412 (53.3 percent) who
could be evaluated, 250 (60.7 percent) were enrolled and matched with 722 control patients; the other
162 patients had no controls. In the case-control study, we found that 68 patients with Bell's palsy (27.2
percent) and 8 controls (1.1 percent) had received the intranasal vaccine (P<0.001). In contrast to
parenteral vaccines, the intranasal vaccine significantly increased the risk of Bell's palsy (adjusted odds
ratio, 84.0; 95 percent confidence interval, 20.1 to 351.9). Even according to conservative assumptions,
the relative risk of Bell's palsy was estimated to be 19 times the risk in the controls, corresponding to 13
excess cases per 10,000 vaccinees within 1 to 91 days after vaccination. In the case-series analysis, the
period of highest risk was 31 to 60 days after vaccination. CONCLUSIONS: This study suggests a
strong association between the inactivated intranasal influenza vaccine used in Switzerland and Bell's
palsy. This vaccine is no longer in clinical use.
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background
 
After the introduction of an inactivated intranasal influenza vaccine that was used only
in Switzerland, 46 cases of Bell’s palsy were reported.
 
methods
 
We conducted a matched case–control study and a case-series analysis. All primary
care physicians, ear, nose, and throat specialists, and neurologists in German-speak-
ing regions of Switzerland were requested to identify cases of Bell’s palsy diagnosed in
adults between October 1, 2000, and April 30, 2001. Each physician was invited to se-
lect three control patients for each patient with Bell’s palsy, with matching according to
age, date of the clinic visit, and physician. Vaccination information was provided by the
physicians.
 
results
 
A total of 773 patients with Bell’s palsy were identified. Of the 412 (53.3 percent) who
could be evaluated, 250 (60.7 percent) were enrolled and matched with 722 control pa-
tients; the other 162 patients had no controls. In the case–control study, we found that
68 patients with Bell’s palsy (27.2 percent) and 8 controls (1.1 percent) had received the
intranasal vaccine (P<0.001). In contrast to parenteral vaccines, the intranasal vaccine
significantly increased the risk of Bell’s palsy (adjusted odds ratio, 84.0; 95 percent con-
fidence interval, 20.1 to 351.9). Even according to conservative assumptions, the rela-
tive risk of Bell’s palsy was estimated to be 19 times the risk in the controls, corre-
sponding to 13 excess cases per 10,000 vaccinees within 1 to 91 days after vaccination.
In the case-series analysis, the period of highest risk was 31 to 60 days after vaccination.
 
conclusions
 
This study suggests a strong association between the inactivated intranasal influenza
vaccine used in Switzerland and Bell’s palsy. This vaccine is no longer in clinical use.
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nfluenza is a leading cause of ill-
 
ness and death.
 
1
 
 Annual vaccination is recom-
mended for certain age groups and high-risk
populations. However, the acceptance of parenter-
al influenza vaccines has frequently been unsatis-
factory, in part because of the fear of injections.
 
2
 
Intranasal administration of influenza vaccines is
an attractive alternative. It might also reduce the
transmission of influenza more efficiently than
parenteral administration by stimulating both mu-
cosal and systemic immune responses.
 
2,3
 
 To date,
two trivalent intranasal influenza vaccines have been
developed. An inactivated virosomal-subunit influ-
enza vaccine licensed in Switzerland (Nasalflu, Ber-
na Biotech) was available for the 2000–2001 influ-
enza season; it contained 
 
Escherichia coli
 
 heat-labile
toxin as a mucosal adjuvant. A different live attenu-
ated, cold-adapted influenza vaccine was recently
licensed in the United States.
 
4
 
No serious adverse events were reported with
the Swiss vaccine in the prelicensure trials con-
ducted among 1218 volunteers during four winter
seasons (1996 to 1999).
 
5-9
 
 It was introduced to the
Swiss market in October 2000 as the first licensed
intranasal influenza vaccine in the world.
During the seven-month period beginning that
month (i.e., October 2000 to April 2001), the Swiss
Drug Monitoring Center and various University of
Zurich institutions received 46 sentinel case re-
ports of Bell’s palsy among recipients of the vac-
cine, including 43 from German-speaking parts of
Switzerland. The media reported these events in
March 2001. Subsequently, Berna Biotech suspend-
ed distribution of the vaccine and invited our insti-
tutions at the University of Zurich to investigate
whether the inactivated intranasal vaccine was as-
sociated with an increased risk of Bell’s palsy. The
Centers for Disease Control and Prevention joined
the investigation in November 2001. The Swiss in-
tranasal vaccine is now no longer in clinical use.
There has been no systematic survey of Bell’s
palsy in Switzerland. The reported incidence of
Bell’s palsy in other countries has ranged from 15
to 40 cases per 100,000 population per year.
 
10-16
 
study design
 
We conducted a matched case–control study in
which patients with Bell’s palsy (case patients) and
control patients were matched according to age,
date of their clinic visit, and physician. Since about
74,000 doses of the intranasal vaccine, or more
than 80 percent of the intranasal-vaccine supply,
were distributed in the 19 German-speaking re-
gions of Switzerland, this region was defined as the
study area. To gain a better understanding of the
timing of the risk for Bell’s palsy after administra-
tion of the intranasal vaccine, we assessed the onset
intervals (i.e., the intervals from the date of the first
dose of the vaccine to the date of the first visit to a
physician for Bell’s palsy) in a larger series of pa-
tients, a method referred to as case-series analysis. 
The study protocol was approved by the ethics
committees of the regions involved in the study. All
the patients gave written informed consent, except
for a small minority with additional cases reported
by physicians anonymously. The academic investi-
gators had access to all the study data, took respon-
sibility for designing and conducting the analysis,
and had authority over the manuscript preparation
and the decisions concerning publication.
 
selection of case patients and controls
 
All 4891 primary care physicians, ear, nose, and
throat specialists, and neurologists in the study area
were invited twice to report cases of Bell’s palsy
first diagnosed between October 1, 2000, and April
30, 2001. The overall response rate was 81.1 per-
cent. Subsequently, the physicians who had report-
ed cases of Bell’s palsy were asked to document the
date of the visit and information pertinent to the
study’s inclusion and exclusion criteria and to select,
from among their patients without Bell’s palsy,
three controls sequentially from their registration
log. The controls were matched with the case pa-
tients according to age (within five years), date of the
clinic visit (within four days), and physician. Trained
study monitors contacted the physicians and re-
viewed the selection forms regularly to ensure con-
sistency in the selection of controls. At this point,
participating physicians had not been made aware
of the exposure to be investigated (influenza vacci-
nation). Thereafter, questionnaires requesting clini-
cal information about the case patients and controls
were sent together with informed-consent forms to
both the physicians and their patients. The patients’
questionnaires were used primarily for validation of
the information provided by the physicians. When
there was a discrepancy, both the patient and the
physician were contacted for clarification.
Patients with Bell’s palsy were eligible for the
i
methods
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study if they were at least 18 years of age and if they
had complete or incomplete unilateral weakness of
the facial muscles. The onset of weakness had to be
sudden, and the progression of facial palsy had to
reach a maximum within one week after the onset
of the first symptoms. Exclusion criteria were head
trauma within two months before enrollment and
a history of brain tumor, cerebrovascular accident,
ipsilateral ear disease or surgery, or the Guillain–
Barré syndrome. Patients were not selected as con-
trols if they met the same exclusion criteria or if they
received a clinical diagnosis of influenza at the in-
dex visit. The exclusion of patients with influenza
as controls was a measure taken in an effort to pre-
vent an overrepresentation of patients with influen-
za as controls during the winter season. Physicians
who were unwilling to select controls were still
asked to document any cases.
 
exposure to influenza vaccines
 
Physicians were asked to document the dates of ad-
ministration and the brand name and type of influ-
enza vaccine (parenteral or intranasal) used during
the study period. Other vaccine exposures during
the study period and the preceding two months
were also documented. Since in all 43 sentinel cases
reported in the study area the onset of Bell’s palsy
occurred within 91 days after intranasal vaccination,
we defined the period of 1 to 91 days as the post-
exposure risk period.
For 10 exposed case patients and 1 exposed
control, we were unable to calculate the onset in-
terval because the date of vaccination was unknown.
We decided to include them in the conditional lo-
gistic-regression analysis on the assumption that
they had an onset interval of 1 to 91 days, because
including them would provide a more conservative
estimate of the adjusted odds ratio for Bell’s palsy
with use of the intranasal vaccine than would ex-
cluding them.
 
covariates
 
Additional information, including potential risk fac-
tors for Bell’s palsy,
 
11-21
 
 was obtained from physi-
cians and patients. Documented information at the
time of enrollment included sex, nationality, preg-
nancy status, smoking status, current infectious
diseases (upper respiratory infections, influenza,
herpes simplex, other herpes infections, borreliosis,
human immunodeficiency virus infection, and 
 
My-
coplasma pneumoniae
 
 infection), chronic diseases (di-
abetes, cardiovascular diseases, hypertension, asth-
ma, allergies, and neoplasm), and a personal or
family history of Bell’s palsy.
 
statistical analysis
 
Matched Case–Control Study
 
The date of the first visit to a physician for Bell’s
palsy was used as the index date and was docu-
mented for all the case patients. The date of admin-
istration of the first dose of the intranasal vaccine
was defined as the exposure date. Conditional lo-
gistic regression (SAS version 8, SAS Institute) was
performed to estimate the risk of Bell’s palsy dur-
ing the period from 1 to 91 days after vaccination
(the predefined risk period), with adjustment for the
potential risk factors defined as covariates.
 
Case-Series Analysis
 
To determine which exposure periods after vacci-
nation were associated with the highest risk of Bell’s
palsy, we performed a case-series analysis.
 
22,23
 
 The
case series included 412 case patients (250 from
the case–control study and 162 from the group of
case patients without controls). We compared the
risk of Bell’s palsy during various periods after intra-
nasal or parenteral vaccination (1 to 30, 31 to 60, and
61 to 91 days, as compared with 92 or more days).
 
Risk Assessment after Adjustment for Biases
 
To assess the presence and the magnitude of selec-
tion bias, we compared the number of case patients
who had been exposed to the intranasal vaccine dur-
ing the case–control study with the number of the
sentinel case patients and with the series of case pa-
tients for whom there were no matched controls.
In addition, we estimated the relative and excess
risks based on the risk in the adult population and
the number of doses of the intranasal vaccine dis-
tributed in the study area.
 
study population
 
A total of 1291 cases of Bell’s palsy were reported
during the seven-month period in the study area.
Eighty-one (6.3 percent) represented duplicate cas-
es, 187 (14.5 percent) involved patients who were
not identifiable in the medical records, and 250
(19.4 percent) involved patients who were ineligi-
ble for the study because they were younger than 18
years of age (34 patients), had an onset of Bell’s
results
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palsy before or after the study period (101), did not
have Bell’s palsy (31), or met one or more exclusion
criteria (84).
Of the remaining 773 patients with Bell’s palsy,
361 (46.7 percent) were not enrolled because their
providers declined to participate; the other 412
(53.3 percent) were enrolled. The diagnosis was
confirmed by a specialist in 298 patients (72.3 per-
cent) and by a primary care physician in 114 (27.7
percent). Of the 412 case patients, 250 (60.7 per-
cent) were matched with 722 controls; the provid-
ers of the remaining 162 case patients declined to
enroll controls.
 
case–control study
 
Table 1 summarizes the characteristics of the case
patients, controls, and all vaccinees. Sixty-eight of
the 250 patients with Bell’s palsy (27.2 percent)
and 8 of the 722 controls (1.1 percent) had received
the inactivated intranasal vaccine (P<0.001). Of the
patients who had not received the intranasal vac-
cine, 27 of the 182 patients with Bell’s palsy (14.8
percent) and 90 of the 714 controls (12.6 percent)
had been immunized with parenteral influenza
vaccine before the index date (Table 2).
Conditional logistic-regression analysis showed
that the adjusted odds ratio for a diagnosis of Bell’s
palsy during the 91-day exposure period among re-
cipients of intranasal vaccine, as compared with
controls, was 84.0 (95 percent confidence interval,
20.1 to 351.9) (Table 2). In contrast, there was es-
sentially no risk of Bell’s palsy after receipt of the
traditional, parenteral influenza vaccine (adjusted
odds ratio, 1.1; 95 percent confidence interval, 0.6
to 2.0). The only risk factor for Bell’s palsy other
than receipt of the intranasal vaccine was a nation-
 
* The crude odds ratio was calculated to assess differences between the intranasally and the parenterally vaccinated pa-
 
tients. CI denotes confidence interval.
 
Table 1. Demographic Characteristics and Underlying Conditions of the Patients with Bell’s Palsy and the Controls.
Variable Case–Control Study
All Vaccine Recipients 
(Case Patients and Controls)
 
Case
Patients
(N=250)
Controls
(N=722)
Additional
Patients with
Bell’s Palsy 
(N=162)
Intranasal
Vaccine 
(N=99)
Parenteral
Vaccine 
(N=130)
Crude Odds
Ratio
(95% CI)
 
*
Demographic characteristic
 
Age — yr
Mean 49.9 50.3 49.7 50.0 54.8
Median 49.7 50.3 48.1 49.0 57.0
Sex — no. (%)
Female 136 (54.4) 389 (53.9) 76 (46.9) 60 (60.6) 73 (56.2) 1.0
Male 114 (45.6) 328 (45.4) 85 (52.5) 38 (38.4) 57 (43.8) 0.8 (0.5–1.4)
Unknown 0 5 (0.7) 1 (0.6) 1 (1.0) 0
Nationality — no. (%)
German-speaking countries 203 (81.2) 569 (78.8) 129 (79.6) 92 (92.9) 114 (87.7) 1.0 
Other countries 21 (8.4) 54 (7.5) 30 (18.5) 1 (1.0) 6 (4.6) 0.2 (0–1.3)
Unknown 26 (10.4) 99 (13.7) 3 (1.9) 6 (6.1) 10 (7.7) 0.7 (0.3–2.1)
 
Relevant diagnosis or intervention
— no. (%)
 
Type 2 diabetes 21 (8.4) 51 (7.0) 17 (10.5) 6 (6.1) 32 (24.6) 0.2 (0.1–0.5)
Hypertension 61 (24.4) 173 (24.0) 40 (24.7) 28 (28.3) 67 (51.5) 0.4 (0.2–0.7)
Asthma 6 (2.4) 41 (5.7) 6 (3.7) 7 (7.1) 11 (8.5) 0.8 (0.3–2.4)
Infectious disease 47 (18.8) 205 (28.4) 32 (19.8) 21 (21.2) 45 (34.6) 0.5 (0.3–1.0)
Upper respiratory infection 35 (14.0) 123 (17.0) 21 (13.0) 13 (13.1) 29 (22.3) 0.5 (0.1–1.1)
Other vaccination 5 (2.0) 27 (3.7) 2 (1.2) 3 (3.0) 4 (3.1) 1.0 (0.2–5.4)
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ality within southern Europe (adjusted odds ratio,
2.4; 95 percent confidence interval, 1.3 to 4.7). In
addition, controls were more likely than case pa-
tients to have an infectious disease, although the dif-
ference was barely significant (adjusted odds ratio,
0.47; 95 percent confidence interval, 0.23 to 0.98).
 
case-series analysis and risk periods
 
In our case-series analysis of 412 patients, we iden-
tified 91 intranasally vaccinated patients with Bell’s
palsy, 81 of whom had adequate data for calculat-
ing onset intervals. Forty-four of these 81 patients
(54.3 percent) first visited a physician because of
symptoms 31 to 60 days after intranasal vaccina-
tion (relative incidence of Bell’s palsy after intranasal
vaccination, 35.6; 95 percent confidence interval,
14.1 to 89.8), 17 (21.0 percent) had an onset inter-
val of 1 to 30 days (relative incidence, 14.0; 95 per-
cent confidence interval, 5.2 to 37.9), 15 (18.5 per-
cent) had an onset interval of 61 to 91 days (relative
incidence, 11.8; 95 percent confidence interval, 4.3
to 32.3), and 5 (6.2 percent) had an onset interval
exceeding 91 days (Fig. 1). The onset intervals in
sentinel cases had a similar distribution, although
in more than one third of the sentinel cases the on-
set interval was 1 to 30 days. In contrast, 61.5 per-
cent of parenterally vaccinated case patients had an
onset interval of more than 91 days. Table 3 provides
data on the neurologic outcome in these patients.
 
risk assessment after adjustment 
for biases
 
We were concerned that in our case–control study
we may have overestimated the risk of Bell’s palsy
after intranasal vaccination, for the following two
reasons. First, sentinel cases had a higher proba-
bility of being included in the case–control study
(22 of 43 cases [51.2 percent]) than nonsentinel
cases (228 of 730 [31.2 percent]) (Table 4). Second,
the proportion of patients with Bell’s palsy who
had been exposed to the vaccine was 27.2 percent
(68 of 250 patients) in the case–control study but
only 14.2 percent (23 of 162 patients) in the series of
case patients without controls (Table 4). We used
two approaches to estimate the total number of ex-
posed case patients in the entire group of 773 pa-
tients with Bell’s palsy in order to adjust for this
likely overestimation.
 
Approach 1
 
We assumed that nonsentinel cases of Bell’s palsy
with vaccine exposure had the same probability of
being included in either the case–control study or
the case series as did sentinel cases. According to
Table 4, this assumption forces the following equa-
tion: (22+5)÷43=(46+18)÷(64+x), which is solved
when x=38 and which yields an estimate of 145 to-
tal (sentinel and nonsentinel) cases with vaccine
exposure.
 
Figure 1. Onset Intervals among the Patients with Bell’s Palsy.
 
Among nonsentinel cases of Bell’s palsy in which the intranasal vaccine had 
been administered, the onset interval was defined as the period from the first 
dose of the intranasal vaccine to the first visit to a physician for Bell’s palsy; 
among sentinel cases, the onset interval was defined as the period from the 
first dose of the intranasal vaccine to the onset of Bell’s palsy. Among cases of 
Bell’s palsy in which a parenteral vaccine had been administered, the onset in-
terval was defined as the period from vaccination to the first visit to a physi-
cian for Bell’s palsy.
Pe
rc
en
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f C
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60.0
40.0
30.0
10.0
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<30 31–60 61–91 >91
Onset Interval (days)
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Intranasal vaccine
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Parenteral vaccines
 
* The date of vaccination (the date of the first dose in the case of intranasal vac-
cine) and the date of the first visit to a physician for Bell’s palsy (the index 
date) were used to determine the onset interval. This information was ob-
tained from the medical records. Case patients and controls were matched ac-
cording to age, date of the clinic visit, and physician. The odds ratios for Bell’s 
palsy were estimated by conditional logistic-regression analysis. CI denotes 
confidence interval.
 
† For 10 case patients and 1 control, the onset interval was unknown.
 
Table 2. Risk of Bell’s Palsy among Participants in the Case–Control Study.*
Vaccine and Bell’s Palsy
Onset Interval
Case Patients
(N=250)
Controls
(N=722)
Adjusted Odds Ratio
(95% CI)
 
no. (%)
 
Intranasal vaccine†
Onset interval ≤91 days 63 (25.2) 7 (1.0) 84.0 (20.1–351.9)
Onset interval >91 days 5 (2.0) 1 (0.1)
Parenteral vaccine
Onset interval ≤91 days 10 (4.0) 41 (5.7) 1.1 (0.6–2.0)
Onset interval >91 days 17 (6.8) 49 (6.8)
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Approach 2
 
The proportion of cases with vaccine exposure was
higher in the case–control study than in the case
series, with an odds ratio of 2.25 (27.2 percent vs.
14.2 percent). We assumed that the odds of expo-
sure in the case series was also 2.25 times the odds
of exposure in the remaining, unreported cases.
This assumption forces the following equation:
[0.142÷(1¡0.142)]÷[(16+x)÷(361¡[16+x])]=2.25,
which is solved when x=9 and which yields an esti-
mate of 116 total exposed cases (Table 4).
The more conservative estimate of 116 cases of
Bell’s palsy with vaccine exposure, as calculated
with the second approach, yields an overall risk as-
sociated with exposure of 15.0 percent (116 of 773
cases overall). Thus, among 250 cases in the case–
control study, one would have expected 38 cases
with exposure, rather than the observed 68. This
suggests that the adjusted odds ratio in the case–
control study may have been overestimated by a fac-
tor of (0.272÷[1¡0.272])÷(0.150÷[1¡0.150]), or
2.1. When we accounted for the overestimation,
the estimate of the adjusted odds ratio was reduced
to 40.0 (84.0 ÷ 2.1).
We identified 107 cases of Bell’s palsy with vac-
cine exposure from all sources of information (Table
4). We assumed that they constituted all the exposed
cases (and that there were no additional instances
of exposure among the 361 nonparticipating pa-
tients with Bell’s palsy). We also had information
on the size of the adult population in the study area
(4.056 million) and on the doses of intranasal vac-
cine that were distributed for 74,000 vaccinees. The
estimated 666 cases of Bell’s palsy without expo-
sure (773 cases overall, minus 107 cases with expo-
sure) over a seven-month period in a population of
3.982 million adults (4.056 million overall, minus
0.074 million vaccinees) yields a rate of 29 cases per
100,000 population per year.
On the basis of the available onset intervals
among the cases of Bell’s palsy with vaccine expo-
sure, we estimated that in 93.8 percent of these cas-
es the palsy developed 1 to 91 days after vaccination.
Combining this result with the minimum number
of 107 for all cases of Bell’s palsy with exposure
would yield 100 as the number of intranasally vac-
cinated patients in whom the palsy developed with-
in 1 to 91 days. This would yield an estimated rate of
541 cases of Bell’s palsy per 100,000 vaccinees per
year, with a relative risk of 19 for the three months
after intranasal vaccination and a corresponding
excess risk of 13 cases per 10,000 vaccinees.
We found that the intranasal influenza vaccine
used in Switzerland during the 2000–2001 influen-
za season greatly increased the risk of Bell’s palsy
among vaccinees. The association was strong, tem-
poral, and specific. The risk was highest during the
second month after intranasal vaccination. In con-
trast, no significant risk of Bell’s palsy was found to
be associated with the parenteral influenza vaccines.
We faced substantial challenges in the process
of collecting data. Because of strict medical-privacy
standards in Switzerland, few physicians would al-
low us to review the medical records on site or off
site, in the form of photocopies. The time required
for physicians to enroll both cases and controls be-
came a formidable burden. Consequently, we were
able to enroll only about one third of the identified
cases in the case–control study. Our data suggested
that patients with Bell’s palsy who had received the
intranasal vaccine were overrepresented in the case–
control study, probably because of the regional me-
dia coverage of this problem. Furthermore, the ex-
act magnitude of the risk associated with use of the
intranasal vaccine was difficult to quantify because
of the small number of controls who had received it.
All these factors raised concern about the ability
of the case–control study to provide unbiased re-
sults. However, even after we adjusted for possible
biases, our risk assessment provided strong evi-
dence supporting our findings. Even with the most
conservative assumption — that the 107 document-
ed cases with exposure were the only such cases —
the association of Bell’s palsy and intranasal vacci-
nation was still overwhelming, with a relative risk
of at least 19 and an excess risk of 13 cases per
10,000 vaccinees. The population-based risk esti-
discussion
 
* Because of rounding, not all percentages total 100.
† Cranial-nerve function (the function of the seventh cranial nerve) was docu-
 
mented by the patients’ physicians.
 
Table 3. Outcome of Patients with Bell’s Palsy.*
Cranial-Nerve Function†
Intranasal Vaccine
(N=91)
Parenteral Vaccine
(N=40)
No Vaccine
(N=281)
 
number (percent)
 
Complete (100%) 73 (80.2) 27 (67.5) 180 (64.1)
Incomplete
≥95%
<95%
15 (16.5)
7 (7.7)
8 (8.8)
7 (17.5)
4 (10.0)
3 (7.5)
62 (22.1)
18 (6.4)
44 (15.7)
Unknown 3 (3.3) 6 (15.0) 39 (13.9)
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mate for the cases of Bell’s palsy without exposure
was within the ranges reported in the literature.
 
10-16
 
The relatively high risk of Bell’s palsy among south-
ern Europeans has been reported previously.
 
24,25
 
We cannot explain the finding that controls were
more likely than case patients to have infectious
diseases, since this variable included multiple dis-
eases, each of which affected only a small number
of patients.
The clinical features of the Bell’s palsy affecting
the patients in this study were consistent with those
described in the literature.
 
21
 
 About one in five pa-
tients in all the groups had an incomplete recovery;
loss to follow-up was more common among par-
enterally vaccinated or unvaccinated patients than
among intranasally vaccinated patients. 
The causes and pathogenesis of Bell’s palsy re-
main unclear. Herpes simplex has been suspect-
ed,
 
26-28
 
 but autoimmune processes have also been
considered.
 
21
 
 The results of studies in animals have
raised concern that the adjuvant 
 
Escherichia coli
 
 heat-
labile toxin may be an inflammatory mediator,
 
3,29
 
but preclinical research on its toxicologic character-
istics and biologic distribution did not support this
idea,
 
30
 
 and neurologic toxicity of this substance in
humans has never been described. Further studies
are needed to investigate the pathogenesis of Bell’s
palsy after use of the inactivated intranasal influenza
vaccine. Adverse neurologic events, such as Bell’s
palsy, should be monitored for at least 60 days
when any intranasal influenza vaccine is tested.
In the prelicensure trials of the intranasal influ-
enza vaccine, no cases of Bell’s palsy were reported
among 1218 recipients (Spyr C, Berna Biotech:
personal communication). However, 46 cases of
Bell’s palsy were reported shortly after licensure.
Historically, the sample sizes for even the largest
phase 3 trials before licensure have been based on
efficacy, not on safety considerations. Unfortunate-
ly, as with the experience with the rotavirus vaccine
and intussusception,
 
31
 
 the risk of Bell’s palsy
found after licensure of the intranasal influenza
vaccine could not have been detected beforehand,
given the sample size in the prelicensure trials.
These experiences may reinforce the arguments
both for larger prelicensure safety trials
 
32
 
 and for
enhanced postlicensure surveillance.
 
33
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* Values for the variable x were found in each of two methods used to evaluate the probable overestimation of the risk 
of Bell’s palsy after intranasal vaccination.
† These case patients were enrolled in both the case–control study and the case-series analysis.
‡ These case patients were enrolled only in the case-series analysis because controls were not made available by the par-
 
ticipating physicians.
 
Table 4. Distribution of Cases of Bell’s Palsy According to the Data-Collection Process and Exposure to the Intranasal Vaccine.*
Case Patients
Cases with
Vaccine Exposure
Cases without
Vaccine Exposure All Cases
Percentage of Cases
with Vaccine Exposure
 
Sentinel Nonsentinel
 
number
 
Enrolled in case–control study† 22 46 182 250 27.2
Enrolled without controls‡ 5 18 139 162 14.2
Not enrolled 16 x 361¡[16+x] 361 ≥4.4
Total 43 64+x 321+[361¡(16+x)] 773
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